Note: Ingredients listed on restricted chemical lists
EC/CAS
500-315-8/127087-87-0
Name of the chemical
Nonylphenolethoxylates (NPEO)
Concentration
#3_T_CONCENTRATION
EC/CAS
9036-19-5
Name of the chemical
Octylphenolethoxylates (OPEO)
Concentration
#3_T_CONCENTRATION
General Information
Version
4.0.0, issued
Revision date
2025-09-25
Product name
LYNOAMP CK19 E - CK19 Primer solution
1.2.1 Relevant identified uses
For in-vitro diagnosis
Emergency telephone
+49 (0)551 192 40
Icons in SDS
Company Information
company name
SYSMEX LTD
e-mail address of the competent person responsible for the Safety Data Sheet
info@sysmex-europe.com
GHS Information
Signal word
-
Hazard Codes
Hazard statements (CLP)
H411
Hazard statements
Code
Statements
H411
Toxic to aquatic life with long lasting effects
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Hazard pictograms
GHS09
Signal word
-
Hazard statements
H411 Toxic to aquatic life with long lasting effects.
Precautionary statements
P273 Avoid release to the environment. P391 Collect spillage.
2.3 Other hazards
The substance/mixture contains components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher. PBT assessment No data available. vPvB assessment No data available.
2.1 Classification of the substance or mixture
Classification in accordance with Regulation (EC) No 1272/2008 (CLP) Aquatic Chronic 2; H411 Classification information This product is assessed and classified using the methods and criteria below referred to in Article 9 of Regulation (EC) n° 1272/2008: Physical hazards: determined through assessment data based on the methods or standards referred to in part 2 of Annex I to CLP Health hazards and environmental hazards: determined through toxicological and ecotoxicological assessment data based on the methods or standards referred to in Part 3, 4 and 5 of Annex I to CLP.